Literature DB >> 20633766

Deletion mapping of chromosome region 12q13-24 in colorectal cancer.

Turkan Aytekin1, Mehmet Ozaslan, Beyhan Cengiz.   

Abstract

Colorectal cancer is one of the most common cancers in the world. Colorectal cancer develops after a long and multistep process of carcinogenesis. Inactivation of tumor suppressor genes is among the most important steps in development of colorectal cancer. Analysis of loss of heterozygosity (LOH) is an effective method to determine the localization of tumor suppressor genes. In this study, we used five microsatellite markers to analyze the region 12q13-24 among 47 patients with colorectal cancer. The frequency of LOH and the clinicopathological data were compared using logistic regression and a chi-square test. In 34 of 47 tumor tissues (72%), LOH was detected at least in one marker. The highest LOH frequency was 34%, on the D12S129 locus; the lowest frequency was 23%, on the D12S78 locus. Loss of heterozygosity was detected as 32% on D12S83, 30% on D12S346, and 26% on D12S1660. No statistically significant correlation was found between the frequency of LOH and clinicopathological features (P > 0.05). Chromosome region 12q13-24 contains several known genes that may be candidate tumor suppressor genes, including RASAL1, ITGA7, STAB2, GLIPR1, and SLC5A8. Although the exact roles of these genes in colorectal cancer formation remain to be clarified, the present data point to a tumor suppressor role. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20633766     DOI: 10.1016/j.cancergencyto.2010.05.005

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  8 in total

1.  Integrin α7 binds tissue inhibitor of metalloproteinase 3 to suppress growth of prostate cancer cells.

Authors:  Lang-Zhu Tan; Yang Song; Joel Nelson; Yan P Yu; Jian-Hua Luo
Journal:  Am J Pathol       Date:  2013-07-02       Impact factor: 4.307

2.  SLC5A8 nuclear translocation and loss of expression are associated with poor outcome in pancreatic ductal adenocarcinoma.

Authors:  James Helm; Domenico Coppola; Vadivel Ganapathy; Mark Lloyd; Barbara A Centeno; Dung-Tsa Chen; Mokenge P Malafa; Jong Y Park
Journal:  Pancreas       Date:  2012-08       Impact factor: 3.327

3.  GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction.

Authors:  Likun Li; Chengzhen Ren; Guang Yang; Elmoataz Abdel Fattah; Alexei A Goltsov; Soo Mi Kim; Ju-Seog Lee; Sanghee Park; Francesco J Demayo; Michael M Ittmann; Patricia Troncoso; Timothy C Thompson
Journal:  Cancer Res       Date:  2011-10-24       Impact factor: 12.701

Review 4.  Somatic gene copy number alterations in colorectal cancer: new quest for cancer drivers and biomarkers.

Authors:  H Wang; L Liang; J-Y Fang; J Xu
Journal:  Oncogene       Date:  2015-08-10       Impact factor: 9.867

5.  Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2.

Authors:  Likun Li; Guang Yang; Chengzhen Ren; Ryuta Tanimoto; Takahiro Hirayama; Jianxiang Wang; David Hawke; Soo Mi Kim; Ju-Seog Lee; Alexei A Goltsov; Sanghee Park; Michael M Ittmann; Patricia Troncoso; Timothy C Thompson
Journal:  Mol Oncol       Date:  2012-12-31       Impact factor: 6.603

Review 6.  Regulation of colonic epithelial butyrate transport: Focus on colorectal cancer.

Authors:  Pedro Gonçalves; Fátima Martel
Journal:  Porto Biomed J       Date:  2016-07-01

Review 7.  Glioma pathogenesis-related protein 1 performs dual functions in tumor cells.

Authors:  Junjie Wang; Zeyu Li; Fenfen Yin; Rui Zhang; Ying Zhang; Zhengxin Wang; Xiumei Sheng
Journal:  Cancer Gene Ther       Date:  2021-03-19       Impact factor: 5.987

8.  A carcinogenic trigger to study the function of tumor suppressor genes in Schmidtea mediterranea.

Authors:  Andromeda Van Roten; Amal Zohir Abo-Zeid Barakat; Annelies Wouters; Thao Anh Tran; Stijn Mouton; Jean-Paul Noben; Luca Gentile; Karen Smeets
Journal:  Dis Model Mech       Date:  2018-08-16       Impact factor: 5.758

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.